Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05839379 · ClinicalTrials.gov registry record
Targeted Pediatric High-Grade Glioma Therapy
A clinical trial of Glioblastoma and Glioblastoma Multiforme, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- 350
- Enrollment target
- 20
- Study locations
NCT05839379: Recruiting study of Glioblastoma and Glioblastoma Multiforme, sponsored by Nationwide Children's Hospital.
NCT05839379 is a study of Glioblastoma and Glioblastoma Multiforme that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 350 participants, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (227% higher). The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05839379, a study of Glioblastoma and Glioblastoma Multiforme, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.
Primary Outcome
Utilize molecular, clinical, and histopathologic data to assess eligibility for specific biologically-guided treatment subprotocols among pediatric, adolescent and young adult patients with newly diagnosed HGG, including DIPG.
Conditions Studied
Study Locations (20)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
North Carolina
- Duke University Health System - Durham
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-08-02 |
| Est. Completion | 2034-08-28 |
What NCT05839379 shows while recruiting
NCT05839379 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (227% higher).
The record links to 9 conditions, with Glioblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT05839379 names 20 study sites across 19 states, led by Ohio, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05839379 about?
NCT05839379 is a clinical study titled "Targeted Pediatric High-Grade Glioma Therapy". The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical t...
What is the current status of trial NCT05839379?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2024-08-02. Estimated completion is 2034-08-28.
What conditions does trial NCT05839379 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, High Grade Glioma, Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma.
Who is sponsoring clinical trial NCT05839379?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05839379 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05839379's enrollment target sits among peer trials
350 17th of 199 higher than 183 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI